Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke

Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke

Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein...

Full description

Bibliographic Details
Main Authors: Karin Weissenborn, Ralf Lichtinghagen, Hans Worthmann, Reinhard Dengler, Wolfgang G. Eisert, Andreas Schwartz, Helmut Schumacher
Format: Article
Language:English
Published: MDPI AG 2012-07-01
Series:International Journal of Molecular Sciences
Subjects:
ischemic stroke
monocyte chemoattractant protein-1 (MCP-1)
antithrombotic therapy
neuroprotection
dipyridamole
acetylsalicylic acid (ASA)
Online Access:http://www.mdpi.com/1422-0067/13/7/8670

Internet

http://www.mdpi.com/1422-0067/13/7/8670

Similar Items